1. Home
  2. SCYX vs WYY Comparison

SCYX vs WYY Comparison

Compare SCYX & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • WYY
  • Stock Information
  • Founded
  • SCYX 1999
  • WYY 1991
  • Country
  • SCYX United States
  • WYY United States
  • Employees
  • SCYX N/A
  • WYY N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • WYY EDP Services
  • Sector
  • SCYX Health Care
  • WYY Technology
  • Exchange
  • SCYX Nasdaq
  • WYY Nasdaq
  • Market Cap
  • SCYX 34.9M
  • WYY 29.5M
  • IPO Year
  • SCYX 2014
  • WYY 1998
  • Fundamental
  • Price
  • SCYX $0.83
  • WYY $4.74
  • Analyst Decision
  • SCYX
  • WYY Strong Buy
  • Analyst Count
  • SCYX 0
  • WYY 2
  • Target Price
  • SCYX N/A
  • WYY $7.50
  • AVG Volume (30 Days)
  • SCYX 167.5K
  • WYY 116.1K
  • Earning Date
  • SCYX 08-13-2025
  • WYY 08-14-2025
  • Dividend Yield
  • SCYX N/A
  • WYY N/A
  • EPS Growth
  • SCYX N/A
  • WYY N/A
  • EPS
  • SCYX N/A
  • WYY N/A
  • Revenue
  • SCYX $3,257,000.00
  • WYY $144,421,640.00
  • Revenue This Year
  • SCYX $422.61
  • WYY $9.19
  • Revenue Next Year
  • SCYX $240.56
  • WYY $10.81
  • P/E Ratio
  • SCYX N/A
  • WYY N/A
  • Revenue Growth
  • SCYX N/A
  • WYY 16.25
  • 52 Week Low
  • SCYX $0.66
  • WYY $2.19
  • 52 Week High
  • SCYX $1.66
  • WYY $6.25
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 54.46
  • WYY 67.08
  • Support Level
  • SCYX $0.82
  • WYY $4.65
  • Resistance Level
  • SCYX $0.88
  • WYY $5.07
  • Average True Range (ATR)
  • SCYX 0.04
  • WYY 0.37
  • MACD
  • SCYX -0.00
  • WYY 0.09
  • Stochastic Oscillator
  • SCYX 48.45
  • WYY 81.87

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

Share on Social Networks: